临床外科杂志 ›› 2025, Vol. 33 ›› Issue (2): 204-207.doi: 10.3969/j.issn.1005-6483.20241929

• 综述与讲座 • 上一篇    下一篇

前列腺癌临床药物研究现状与发展

  

  1. 430030   武汉,华中科技大学同济医学院附属同济医院泌尿外科(李先缪、依日夏提江·阿米尔、胡嘏),老年医学科(吴焕磊)
  • 收稿日期:2024-12-06 接受日期:2024-12-06 出版日期:2025-02-20 发布日期:2025-02-20
  • 通讯作者: 胡嘏,Email:jiahu@tjh.tjmu.edu.cn

Current status and development of clinical drug research for prostate cancer

  1. Department of Urology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China
  • Received:2024-12-06 Accepted:2024-12-06 Online:2025-02-20 Published:2025-02-20

摘要: 前列腺癌是世界范围内最常见的泌尿系统肿瘤,也是欧美男性发病率最高的恶性肿瘤。对于复发或者转移性前列腺癌,目前公认的治疗基石是雄激素剥夺疗法。几乎所有病人最终难以避免地进展至不可治愈的去势抵抗前列腺癌阶段。尽管在过去的20年间,多种新药的获批提高了晚期前列腺癌病人的生存时间和生活质量,但寻找新的策略来克服耐药性产生并进一步提高生存时间仍是亟待解决的难题。本综述基于已发表或正在进行的临床研究,重点概述前列腺癌药物治疗领域所取得的重大进展,以及正在积极开展临床试验的新型药物。

关键词: 去势抵抗性前列腺癌, 药物治疗, 研究进展

Abstract: Prostate cancer is the most prevalent tumor of the urinary system globally and represents the highest incidence of malignant tumors among males in Europe and the United States.For recurrent or metastatic disease,androgen deprivation therapy is currently recognized as the cornerstone of treatment.However,nearly all patients inevitably progress to an incurable castration-resistant prostate cancer stage.Although the approval of several new drugs over the past two decades has enhanced both survival time and quality of life for patients with advanced prostate cancer,there remains an urgent challenge to develop new strategies that can overcome drug resistance and further extend survival duration.Therefore,based on published or ongoing clinical studies,this review will focus on an overview of the significant advancements made in the field of prostate cancer drug therapy,as well as new drugs that are actively undergoing clinical trials to provide a reference for the clinical treatment of advanced prostate cancer.

Key words: castration resistant prostate cancer, drug therapy, research progress

[1] 樊非睦 董汉华. 胆管癌靶向治疗进展[J]. 临床外科杂志, 2023, 31(4): 394-397.
[2] 郭欣怡 俞亚红. 晚期胰腺癌免疫治疗与靶向治疗研究进展   [J]. 临床外科杂志, 2023, 31(11): 1107-1110.
[3] 李凡, 管维. 肾癌诊疗相关进展[J]. 临床外科杂志, 2021, 29(2): 101-104.
[4] 李干斌 韩加刚 王振军. 肥胖促进恶性肿瘤发生的机制探讨及研究进展[J]. 临床外科杂志, 2021, 29(10): 996-998.
[5] 周春根, 倪敏, 朱勇, 张睿, 黄小波, 张琪, 王领, 刘艳妮, 江滨. 肛瘘微创治疗的研究进展[J]. 临床外科杂志, 2020, 28(2): 190-192.
[6] 李宗光 韩竹 吉光荣. 腕管综合征的临床研究进展 [J]. 临床外科杂志, 2013, 21(5): 394-396.
[7] 倪杨明 徐皓. 颈前路减压融合术后邻近节段退行性变的研究进展[J]. 临床外科杂志, 2012, 20(2): 139-139.
Viewed
Full text
5
HTML PDF
Just accepted Online first Issue Just accepted Online first Issue
0 0 0 0 0 5

  From Others local
  Times 1 4
  Rate 20% 80%

Abstract
71
Just accepted Online first Issue
0 0 71
  From Others local
  Times 69 3
  Rate 96% 4%

Cited

Web of Science  Crossref   ScienceDirect  Search for Citations in Google Scholar >>
 
This page requires you have already subscribed to WoS.
  Shared   
  Discussed   
[1] 黄洪锋. 关注公民逝世后器官捐献肾移植受体围手术期感染的预防与处理[J]. 临床外科杂志, 2016, 24(10): 732 .
[2] 昌盛. 中国心脏死亡捐献供肾器官的维护[J]. 临床外科杂志, 2016, 24(10): 744 .
[3] 杨华;李新长;龙成美;等. 公民逝世后器官捐献供肾移植临床分析[J]. 临床外科杂志, 2016, 24(10): 747 .
[4] 石宇;刘学刚 . 冠状动脉旁路移植术后短期内应用强化他汀对患者出血风险的研究[J]. 临床外科杂志, 2016, 24(10): 750 .
[5] 陈忠;王耀东;田毅峰;等. 肝胆管结石病规范化治疗的临床分析[J]. 临床外科杂志, 2016, 24(10): 753 .
[6] 江帆;孙权;吴国俊;等. 不同引流方式对恶性梗阻性黄疸患者细胞免疫的影响[J]. 临床外科杂志, 2016, 24(10): 760 .
[7] 胡志伟;汪忠镐;张玉;等. 腹腔镜Toupet胃底折叠术治疗干燥综合征合并严重胃食管反流病两例[J]. 临床外科杂志, 2016, 24(10): 766 .
[8] 李光焰;张安平;王祥峰;等. 直肠癌切除术后吻合口狭窄14例分析[J]. 临床外科杂志, 2016, 24(10): 772 .
[9] 胡小平;王志维;邓宏平;等. 改良全主动脉弓置换治疗老年Stanford A型主动脉夹层[J]. 临床外科杂志, 2016, 24(10): 777 .
[10] 宋华;单若冰;张晋绥;等. 产前超声诊断对新生儿消化道梗阻性疾病手术治疗价值的观察[J]. 临床外科杂志, 2016, 24(10): 780 .